Titan Pharmaceuticals Share Price

TTNP

US8883147055

Real-time Estimate Cboe BZX 12:52:22 02/10/2026 am IST			5-day change	1st Jan Change
0.6170 ^USD	+18.65%		-5.28%	-85.99%

04/25/04	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/25/02	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI

Valuation: Titan Pharmaceuticals

Market Cap	61.32L 54.47L 50.94L 46.42L 87.39L 59Cr 88.59L 6.16Cr 2.39Cr 30Cr 2.3Cr 2.25Cr 97Cr	P/E 2023	-1.11x	P/E 2024	-0.62x
Enterprise Value	33.01L 29.32L 27.42L 24.99L 47.04L 32Cr 47.69L 3.32Cr 1.28Cr 16Cr 1.24Cr 1.21Cr 52Cr	EV / Sales 2023	0.11x	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

* Estimated data More valuation ratios

Latest news: Titan Pharmaceuticals

04/25/04	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/25/02	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI
01/25/01	Titan Pharmaceuticals, Inc.(NasdaqCM:TTNP) dropped from NASDAQ Composite Index	CI
01/25/01	Ke Sdn. Bhd. completed the acquisition of Titan Pharmaceuticals, Inc. in a reverse merger transaction.	CI
15/25/15	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
27/25/27	Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
24/25/24	Titan Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
15/25/15	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
12/25/12	Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock	RE
11/25/11	Titan Pharmaceuticals, Inc. announced that it has received $1 million in funding	CI
02/25/02	Titan Pharmaceuticals, Inc. Appoints Gabriel Loh as an Independent Director and Member of the Audit Committee	CI
29/25/29	Titan Pharmaceuticals, Inc. announced that it expects to receive $1 million in funding	CI
21/25/21	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

More news

Analysts' recommendations: Titan Pharmaceuticals

26/22/26	Maxim Downgrades Titan Pharmaceuticals to Hold From Buy	MT
18/21/18	Titan Pharmaceuticals : Maxim Group Upgrades Titan Pharmaceuticals to Buy From Hold, $11 Price Target	MT

More recommendations

Press Releases: Titan Pharmaceuticals

15/25/15	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/25/06	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
28/25/28	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock	AQ
03/25/03	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.	AQ
15/25/15	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ

More press releases

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Employees

Sector

More about the company

Quotes

Date	Price	Change
02/26/02	$0.6257	+20.33%
30/26/30	$0.5200	+12.31%
29/26/29	$0.4630	+6.73%
28/26/28	$0.4338	-12.91%
25/26/25	$0.4981	-7.98%

Delayed Quote Nasdaq

More quotes

1 day	+18.08%
Current month	-85.99%
Current year	-85.99%

3 years	0		14.8
5 years	0		40.6
10 years	0		21,996.03

	2023	2024
Net sales	2L 2L 2L 1L 3L 1.77Cr 3L 18.49L 7L 90.22L 7L 7L 2.9Cr	-
Net income	-55.69L -49.46L -46.26L -42.15L -79.36L -54Cr -80.45L -5.6Cr -2.17Cr -27Cr -2.09Cr -2.05Cr -88Cr	-47.06L -41.8L -39.09L -35.62L -67.06L -45Cr -67.98L -4.73Cr -1.83Cr -23Cr -1.77Cr -1.73Cr -74Cr
Net Debt	-61.95L -55.02L -51.46L -46.89L -88.28L -60Cr -89.49L -6.23Cr -2.41Cr -30Cr -2.33Cr -2.28Cr -98Cr	-28.31L -25.14L -23.51L -21.43L -40.34L -27Cr -40.9L -2.84Cr -1.1Cr -14Cr -1.06Cr -1.04Cr -45Cr

Titan Pharmaceuticals Share Price

Stocks

TTNP

US8883147055

Valuation: Titan Pharmaceuticals

Chart: Titan Pharmaceuticals

Latest news: Titan Pharmaceuticals

Analysts' recommendations: Titan Pharmaceuticals

Press Releases: Titan Pharmaceuticals

Quotes and Performance

Price Extremes

Financials

Company Profile

Quotes